These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24870872)

  • 21. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
    Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M
    Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refining therapeutic strategies for patients with resistant Wilm's tumor.
    Marina NM; Wilimas JA; Meyer WH; Jones DP; Douglass EC; Pratt CB
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):296-300. PubMed ID: 7978044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
    Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety.
    Grafe C; Semrau S; Hein A; Beckmann MW; Mackensen A; Dörje F; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Feb; 391(2):219-229. PubMed ID: 29294142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
    Sibon D; Ertault M; Al Nawakil C; de Bazelaire C; Franchi P; Brière J; de Kerviler E; Beranger N; Thieblemont C; Brice P
    Br J Haematol; 2011 Apr; 153(2):191-8. PubMed ID: 21385169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
    Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
    Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose chemotherapy for salvage treatment of germ cell tumors: Charité, Virchow Klinikum, Berlin.
    Siegert W; Rick O; Beyer J
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S7-9. PubMed ID: 9916622
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.
    Tarhini AA; Zahoor H; McLaughlin B; Gooding WE; Schmitz JC; Siegfried JM; Socinski MA; Argiris A
    Anticancer Res; 2013 Oct; 33(10):4475-81. PubMed ID: 24123018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
    Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
    Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
    Vose JM
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose chemotherapy and ASCR of patients with relapsed or refractory germ cell tumors: long-term follow-up.
    Siegert W; Beyer J
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S60. PubMed ID: 8899176
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.